3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
20
Neoplasm Metastasis
4
Neoplasms
3
Melanoma
3
Thyroid Neoplasms
1
Thymus Neoplasms
1
Thrombosis
1
Thromboembolism
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Inflammation
1
Immune System Diseases
1
Hormone Receptor Positive Advanced Breast Cancer
1
Head and Neck Neoplasms
1
HER2+ Breast Cancer
1
Gastrointestinal Neoplasms
1
Estrogen Receptor-positive Breast Cancer
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
ER Positive, HER2 Negative Breast Cancer
1
Colonic Neoplasms
1
Chordoma
1
Cardiovascular Diseases
1
Interventions
Gonadotropin-Releasing Hormone
2
xinmailong
1
palbociclib
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
Vitamin B 6
1
Vitamin B 12
1
Testosterone
1
Rivaroxaban
1
Progesterone
1
Genetic Testing
1
Folic Acid
1
Estradiol
1
DNA
1
Cardiovascular Agents
1
Blood Specimen Collection
1
Antineoplastic Agents
1
Absorptiometry, Photon
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Cardiovascular Diseases
×
palbociclib
×
Clear all
NCT06065592
2023-10-06
CAT_PB
Lebanese University
Phase 1
Unknown
500 enrolled